...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trading
Reply New Message
Prev Message Back To Forum Threaded View Next Message

"The Issuer has not filed the following periodic disclosure required by the Legislation:
(a) annual audited financial statements, annual management’s discussion and analysis
and certification of the annual filings for the year ended 30 April 2022."

Annual Filing, year end, 30 April 2022, now all on SEDAR and Zenith's Website 

 

Koo

 

 

4 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply